Clinical trial · Interventional
Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical study is to determine impact of carbon ion radiotherapy (CIRT) treatment in combination with systemic therapy for oligo-metastatic prostate cancer. The primary objective: to determine disease biochemical progression-free survival in man with oligo-metastatic (M1a/b) prostate cancer undergoing systemic therapy with definitive radiotherapy of the primary tumor. The secondary objective: to determine local control, overall survival and quality of life in men with oligo-metastatic prostate cancer undergoing carbon ion radiotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Prostate Carcinoma | Prostate Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CIRT with systemic therapy arm | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CIRT with systemic therapy arm
- description
- Carbon ion radiotherapy combined with systemic therapy
- interventionNames
- Radiation: CIRT with systemic therapy arm
Primary outcomes (1)
- measure
- Time to PSA relapse
- timeFrame
- From the start of systemic therapy, a median of 2 years
Secondary outcomes (3)
- measure
- progression free survival
- timeFrame
- From the start of systemic therapy, a median of 2 years
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathologically confirmed adenocarcinoma of the prostate 2. Age ≥ 20 and \< 80 years of age 3. ECOG PS 0 or 1 4. Life-expectancy ≥1 year 5. Stage T1-4,N0-1,M1a/b disease on imaging, with a combined maximum of 3 synchronous lesions. 6. Ability to understand and willingness to sign informed consent Exclusion Criteria: 1. No pathologically confirmed adenocarcinoma of the prostate 2. visceral metastasis 3. Previous pelvic radiotherapy or prostatectomy 4. Severe systemic disorders
References
Publications (0)
Data not yet available